688428 (688428) News
Track canonical SquawkNews coverage tagged to 688428, 688428. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Eli Lilly, InnoCare Sign Deal That Could Top $3 Billion
By Fabiana Negrin OchoaChina-based biopharmaceutical company InnoCare Pharma has signed a research and license agreement with Eli Lilly that could be valued at more than $3 billion.InnoCare, a specialist in cancer and au
NEWS | Sep 24, 2026, 04:54 AM UTC
L
InnoCare Pharma Signs Lilly R&D, Upfronts Up To $100M, Milestones Up To $3.25B
InnoCare Pharma entered a research collaboration and license deal with Eli Lilly, with up to $100M in upfront/near-term payments and up to ~$3.25B in milestones, plus single-digit tiered royalties.Material DetailsContext
NEWS | Sep 24, 2026, 04:23 AM UTC
L
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company ha
NEWS | Sep 24, 2026, 04:22 AM UTC
L
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
Chinese drugmaker InnoCare Pharma SSE:688428 said on Thursday it entered into a research collaboration and license agreement with Eli Lilly NYSE:LLY that could be worth up to about $3.35 billion.
GEOPOLITICS | Sep 24, 2026, 04:19 AM UTC